-transparent.png){kind=logo}
26 patients with impaired renal function and 7 healthy subjects received an oral dose of 0.5 mg 14-Hydroxy-3-beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (meproscillarin, Clift) per day for 2 weeks. Plasma levels of meproscillarin were measured during and after this period by means of the 86Rb-erythrocyte method. No statistically significant differences were found between the 2 groups. The results are consistent with extrarenal elimination of the substance. Contrary to digoxin, e.g., dose reduction is unnecessary in chronic renal failure. Mild gastrointestinal symtpoms were the only side effects seen in 6 patients.
Related Publications
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
January 1978,
Arzneimittel-Forschung,
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
November 1979,
Medizinische Klinik,
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
January 1978,
Arzneimittel-Forschung,
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
September 1980,
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
January 1978,
Arzneimittel-Forschung,
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
June 1978,
Deutsche medizinische Wochenschrift (1946),
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
January 1978,
Arzneimittel-Forschung,
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
August 1978,
Deutsche medizinische Wochenschrift (1946),
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
January 1977,
Arzneimittel-Forschung,
W D Twittenhoff, and
W D Brittinger, and
D W Deckert, and
G G Belz, and
I Schubert
February 1982,
La Nouvelle presse medicale,
